← Back to 52-Week Low Lens

JMDC INC

Company Overview

JMDC is a Japanese healthcare data and telemedicine company listed on the TSE Prime market. It aggregates anonymized medical claims, health-check, pharmacy, and increasingly hospital-originated data; packages that data into analytics and workflow services for insurers, pharmaceutical companies, and medical providers; and also runs a tele-radiology network. The business is best understood as a permissioned healthcare-data platform, not as a hospital or drug company.

The data is reasonably fresh, but not all of it has the same reliability. The latest clean audited annual base is FY2025. More recent data is the FY2026 full-year results release announced on 2026-05-08, which is official but unaudited until the annual securities report is filed, scheduled for 2026-06-24. For price-sensitive metrics, I use the 2026-05-11 closing price of ¥2,665, the first full trading session after the FY2026 release and the cleanest post-result market read available.

Those growth numbers are real, but they need context. FY2026 added another 20.9% revenue growth, yet reported net income fell 7.0%. That headline decline is misleading because FY2025 included discontinued-operation profit from the pharmacy-support business sale. On continuing operations, parent profit actually rose from ¥5.821bn to ¥6.765bn. The business is still growing; the current argument is about the quality and durability of that growth, not whether growth existed.

How the Company Makes Money

JMDC has two engines. The first, and far more important one, is Health Big Data: data services and workflow tools sold to insurers, pharma, and medical providers. The second is Telemedicine, mainly remote image interpretation through DoctorNet. Most of the economics come from the first segment; the second is smaller but highly profitable and strategically useful.

Within Health Big Data, FY2026 revenue was split across three concrete buckets: industry, mainly pharma and insurers, at ¥16.355bn; insurers and consumers at ¥10.889bn; and medical providers at ¥17.203bn. That last bucket is important. It shows JMDC is no longer just reselling insurer-side claims data; it is pushing deeper into provider workflows and hospital-originated data.

What is actually driving growth? Two things. First, the raw data pool keeps widening: the number of contracted health-insurance societies rose from 274 in April 2021 to 416 in April 2025, covered lives grew from 9.3 million to 19.96 million over the same span, and FY2026 management materials put the latest covered-life figure at 20.76 million. Pep Up IDs, JMDC’s personal health record platform, expanded from 2.18 million in FY2021 to 7.39 million in FY2025 and 8.03 million in FY2026 company materials. Second, JMDC keeps monetizing richer datasets into higher-value use cases for pharma and providers. Health Big Data segment revenue went from ¥19.1bn in FY2023 to ¥24.9bn in FY2024, ¥35.6bn in FY2025, and ¥44.1bn in FY2026. That is the real growth engine.

There is also an important post-FY2025 strategic update. After the audited FY2025 base, JMDC announced partnerships with hospital IT players, including Software Service in December 2025 and Fujitsu Japan in February 2026, to widen access to hospital-originated data and electronic medical record-linked use cases. These are company updates, not yet mature enough to show up cleanly in audited numbers, but strategically they matter because they can deepen the moat rather than dilute it.

Owner earnings sanity check. Using a deliberately conservative net-income-based approach on FY2026:

• Net income: ¥6.765bn
• Less sustaining capex: roughly ¥1.5-2.0bn (my estimate)
• Less working-capital drag: roughly ¥0.8bn (my estimate, based on receivables, payables, and contract liabilities)
• Rough owner earnings: about ¥4.0-4.5bn (my estimate)
• Owner earnings yield: about 2.3%-2.6%

Yes, that is meaningfully lower than the 25.8x P/E would suggest. The reason is simple: JMDC is still absorbing cash in platform buildout, data-processing complexity, and working capital. A looser cash view is less harsh: FY2026 operating cash flow minus non-M&A PP&E and intangible cash capex was about ¥6.5bn. The spread between those two views is exactly why the stock is not obviously cheap just because it fell.

Capital efficiency. Recent ROE has mostly sat around 7%-10%, and ROIC has been around the high single digits. That is solid, but it is not elite. More importantly, incremental capital is not obviously earning great returns. Goodwill rose from ¥19.2bn in FY2022 to ¥39.8bn in FY2023, ¥58.4bn in FY2025, and ¥62.6bn in FY2026, while group-level ROE did not move up with it. This is a durable franchise, but it is not yet proving itself as a high-return compounder on incremental capital.

Business quality. The real profit pool is the permissioned data asset and the workflow relationships around it. JMDC’s advantage comes from scale, privacy/compliance know-how, embedded insurer and provider relationships, and the time depth of longitudinal medical data. In telemedicine, the moat is the network of radiologists and institutions. This has been a good business because those assets are hard to assemble and harder to trust. But it is not magic software. It still needs sales execution, data processing, and capital allocation discipline. No customer accounts for more than 10% of revenue, which reduces single-customer fragility. Share-based compensation appears immaterial in the available official data and does not change the thesis.

Why the Stock Fell

The share price decline is the market marking down expectations, not discovering fraud or balance-sheet stress. On 2026-05-11, the stock closed at ¥2,665, down ¥700 or 20.8% in one session, roughly 46% below the 52-week high of ¥4,950 and close to the bottom of its one-year range. That move makes sense once you look at the gap between what JMDC delivered, what it had guided before, and what the market seems to have expected next.

The core issue was not demand collapsing. FY2026 revenue still grew 20.9%, and FY2027 company guidance still calls for another 19.9% revenue growth. The issue was growth-to-profit conversion. Q4 FY2026 revenue was about ¥13.97bn, up about 15.5% YoY, but Q4 operating profit fell about 9.8% YoY. Q4 EBITDA still increased, but only about 5.5%, well below what investors were probably extrapolating from the very strong first nine months.

Management’s own explanation was unusually clear. In its FY2026 briefing materials, JMDC said Q4 fell short because of temporary issues in data processing and sales-resource reallocation in the business serving pharmaceutical-company medical departments. It quantified the gap versus the initial EBITDA outlook as roughly ¥920m of temporary impact plus roughly ¥400m of strategic spending on new business and AI. The market heard a different message: the investment-harvest phase is being pushed out again.

One more nuance matters. Reported FY2026 parent profit fell 7.0%, but FY2025 contained ¥1.454bn of discontinued-operation profit from the Noah Medical sale. On continuing operations, parent profit rose 16%. That does not erase the selloff, because the selloff was about forward margins and the quality of guidance, not the backward-looking headline.

What the Market Is Assuming

(a) One-time, cyclical, or sentiment-driven factors

• The 2026-05-11 limit-down move was a violent de-rating of expectations after a guide miss.
• The headline 7% net-income decline reinforced the negative reaction, even though it was distorted by discontinued operations.
• The Q4 execution stumble may reflect timing, not lasting demand destruction.

(b) Medium-term business headwinds

• Pharma-related medical-department sales are harder to convert than investors thought.
• Data-processing complexity is rising as JMDC broadens datasets and use cases.
• Management is still spending on AI and new-business buildout instead of harvesting margins.
• EBITDA margin may have settled into the mid-20s rather than expanding back toward the old 30% level.
• Cash conversion is weaker than the historical growth narrative implied.

(c) Potential long-term structural threats

• Privacy or healthcare-data regulation could make data access more costly or less exclusive.
• Hospital IT and EHR vendors could retain more of the value chain and commoditize parts of JMDC’s data advantage.
• M&A-heavy growth could keep goodwill high and per-share returns mediocre.
• A major data breach would damage the trust layer of the business, which is central to the moat.

Temporary or Structural?

My diagnosis: mostly TIME, not ESSENCE. The current problem is primarily a growth-quality and execution problem, not clear evidence that the core value-creation engine has broken. The one area that does have an essence flavor is capital allocation: JMDC’s moat is real, but its reinvestment engine has not yet proven itself to be exceptional.

Reality check versus market narrative.

1. Regulatory tightening in medical-data use. The damaged mechanism would be JMDC’s proprietary data-acquisition funnel. If anonymous medical-data rules tighten or data rights become less exclusive, the raw material feeding insurer, pharma, and provider analytics becomes scarcer or more expensive. That would weaken the moat in a way management could not repair inside three years. Classification: (b) Real structural but survivable.

2. M&A-led growth and rising goodwill. The damaged mechanism here is the reinvestment loop, not the current customer franchise. If acquired assets do not earn through, JMDC can remain a good business while still being a mediocre stock. Time can stop future damage, but it cannot reverse past overpayment. Classification: (b) Real structural but survivable.

3. The pharma medical-department stumble and temporary data-processing issue. The damaged mechanism is sales execution and delivery throughput. That is fixable. It does not currently show up as customer loss, data-pool shrinkage, or weakening network scale. Classification: (c) Not truly structural.

4. AI and EHR vendors could erode data uniqueness. The damaged mechanism would be pricing power based on proprietary data. Today I do not see evidence that this has happened. In fact, JMDC’s recent hospital-data partnerships suggest the moat may be broadening. Classification: (c) Not truly structural today.

I do not see clear evidence of (a) Real structural damage in the current numbers. The market is reacting to a miss and a reset, not to proven franchise impairment.

Is the Market Wrong? By How Much?

Time-as-a-moat test. Assume I had JMDC’s current market cap, roughly ¥174bn, in cash and wanted to build a competitor.

So the moat is real. The market is wrong if it is treating the Q4 miss as proof that the moat has broken. The market is right if it is refusing to pay the old premium multiple until JMDC proves that its data moat can convert into cleaner cash earnings and better returns on capital.

This is a FY2027-guidance-based valuation adjusted for the disclosed FY2026 temporary miss. The cash-earnings numbers below are my own estimates, not company guidance.

At the 2026-05-11 close, JMDC’s enterprise value was roughly ¥187bn ex-lease. Against my base normalized cash-earnings estimate of ¥8.0bn, the market is implying about a 4.3% cash yield. I think that is somewhat too punitive on the permanence of the problem, but not wildly so. In yen terms, my base case is about ¥14bn above the market cap, or roughly ¥210 per share.

The catch is important. If FY2026’s harsh owner-earnings sanity check of only about ¥4.0-4.5bn is the true steady state, the stock is not cheap at all. So the investment case depends on believing that the Q4 miss was mainly temporary and that working-capital and investment drag normalize. That makes JMDC fair-to-moderately attractive, not a fat pitch. This is an intrinsic value range, not a price target.

Key Facts, Estimates, and Judgments

Moat & mispricing score: 6/10. JMDC still has a real moat: insurer-side data access, privacy-grade processing, growing provider-side datasets, and a tele-radiology network cannot be rebuilt quickly. I think the market is mostly wrong on essence; the disclosed problems look like execution and investment timing, not franchise breakage. But the market is only modestly wrong on price, because JMDC still converts less of its accounting growth into owner earnings than a true premium compounder should. At ¥2,665, the stock looks somewhat cheaper than fair value, not dramatically mispriced.

• Hard official financial data: FY2025 audited revenue was ¥41.7bn and operating profit ¥8.7bn. FY2026 official full-year results release showed revenue of ¥50.5bn, operating profit of ¥10.5bn, parent profit of ¥6.8bn, cash of ¥29.0bn, and borrowings of ¥41.5bn. FY2026 is official but unaudited until the securities report is filed.
• Company guidance: FY2027 guidance calls for revenue of ¥60.5bn, operating profit of ¥11.5bn, EBITDA of ¥15.0bn, parent profit of ¥7.1bn, and EPS of ¥108.19.
• Market data: I use the 2026-05-11 close of ¥2,665 and an estimated market cap of roughly ¥174bn.
• Analyst estimate: Before the result, the market appears to have been modeling FY2027 operating profit above ¥14bn. That expectation reset explains most of the one-day collapse.
• My estimates: Sustaining capex around ¥1.5-2.0bn; FY2026 rough owner earnings around ¥4.0-4.5bn; normalized FY2027-like cash earnings of ¥7.0-9.0bn; intrinsic equity value range of about ¥143bn to ¥228bn, with a base case near ¥188bn.
• Judgment: The issue is mostly TIME, not ESSENCE. The moat remains real, but JMDC still has to prove it can turn that moat into cleaner owner earnings and better incremental returns. That is why the stock is interesting after the crash, but not obviously cheap.

CoffeeAnd — 52-week low lens